1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Better Understanding of the Safety and Efficacy of a Drug
4.2.2 Cost-effectiveness and Less Chances of Termination of the Trial
4.3 Market Restraints
4.3.1 Unavailability of Complex Testing Centers and Results Based on Approximation
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapeutic Area
5.1.1 Oncology
5.1.2 Infectious Disease
5.1.3 Cardiology
5.1.4 Neurology
5.1.5 Diabetes
5.1.6 Others
5.2 By Industry
5.2.1 Medical Devices
5.2.2 Pharmaceutical
5.3 By Phase
5.3.1 Phase I
5.3.2 Phase II
5.3.3 Phase III
5.3.4 Phase IV
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novadiscovery
6.1.2 Insilico Medicine, Inc.
6.1.3 Dassault Systemes
6.1.4 GNS Healthcare
6.1.5 Immunetrics Inc.
6.1.6 InSilicoTrials Technologies
6.1.7 Clarivate
6.1.8 Evotec
6.1.9 Abzena Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Novadiscovery
- Insilico Medicine, Inc.
- Dassault Systemes
- GNS Healthcare
- Immunetrics Inc.
- InSilicoTrials Technologies
- Clarivate
- Evotec
- Abzena Ltd